For Policy Makers. Making migraine a European health, social and research priority. EMHA CALL TO ACTION Migraine in Europe Time to act now! Migraine is a neglected neurological disease that affects over 41 million people in the European Union (EU). It is labelled as the second leading cause of disability in the world and the
Nancy Baum Lipsitz remembers the night the pain began. She’d had a glass of white wine with a friend and went to bed with a terrible headache. The next day, she still felt horrible, the beginning of what she called a “rolling tide” of near constant migraines and lower level headaches. For three years she
Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its- kind treatment specifically designed for migraine prevention Jul 30, 2018 New Aimovig Medication Approved Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month.
XPatient Barcelona Congress 2021 With the participation of EMHA. The XPatient Barcelona Congress is one of the main actions promoted by the XPA Barcelona (Patient Experience) – a community of practice that brings together institutions from the hospital, technology, research and administration fields – to transform the care model so that it places the patient
EU social summit 2021: The Portuguese Presidency of the Council of the European Union is holding a High-Level Conference and an Informal Meeting. of Leaders at the invitation of the President of the European Council. The Summit will give political impetus to the implementation of the European Pillar of Social Rights and its Action Plan, underlining its
On 22 September 2020, the European Migraine & Headache Alliance organised ‘The Missing Lesson’ webinar to raise awareness about migraine at EU level and kick-start its EU policy advocacy campaign to make migraine a European health priority. The webinar focussed on the medical curriculum deficit when it comes to migraine. This leads to under- diagnosis
EMHA’s 2019 Activities report and agenda of 2019 was fulfilled with activities, meetings and actions under the campaign name of #LightToMigraine. Read the full activities report. Click here to read the complete report.
All the articles are based on the survey led by EMHA on Migraine at work. The objective of this study is to know the situation of migraine workers within the workplace and compare the situation in the different participating countries. In this way, and with the resulting data, the implementation of actions to improve the
The largest patient online event in the world for headache returns this April 18-26.
The Migraine World Summit will bring together over 30 top experts, doctors and specialists to share new treatments, research and strategies for migraine and chronic headache. It is available to anyone with an internet connection.
What is headache? Common neurological disorders Headache disorders are among the most common neurological disorders. These include tension-type headache (TTH), migraine and chronic daily headache syndromes as well as the more rare disorders, cluster headache and trigeminal neuralgia. Underestimated and under-diagnosed Headache has been, and continues to be, underestimated in scope and scale and headache
